Latest Recce Pharmaceuticals (ASX:RCE) News

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Recce Pharmaceuticals has secured a second Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to test its RECCE 327 Gel in burn wound infection models, underscoring growing military interest in its synthetic anti-infectives.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.